Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + CapeOx neoadjuvant study in rectal cancer
ChiCTR2100054709Phase 4Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, capecitabine and oxaliplatin in rectal cancer, sponsored by Henan Provincial People's Hospital. Primary endpoint: R0 resection rate. Started Nov 2021; status: recruiting.
02
Drugs
Rivoceranibcapecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2100054709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054709.